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Hyperchlorhidrosis Caused by Homozygous Mutation
in CA12, Encoding Carbonic Anhydrase XII
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Excessive chloride secretion in sweat (hyperchlorhidrosis), leading to a positive sweat test, is most commonly indicative of cystic fibrosis
yet is found also in conjunctionwith variousmetabolic, endocrine, and dermatological disorders. There is conflicting evidence regarding
the existence of autosomal-recessive hyperchlorhidrosis. We now describe a consanguineous Israeli Bedouin kindred with autosomal-
recessive hyperchlohidrosis whose sole symptoms are visible salt precipitates after sweating, a preponderance to hyponatremic dehydra-
tion, and poor feeding and slow weight gain at infancy. Through genome-wide linkage analysis, we demonstrate that the phenotype is
due to a homozygous mutation in CA12, encoding carbonic anhydrase XII. The mutant (c.427G>A [p.Glu143Lys]) protein showed 71%
activity of the wild-type enzyme for catalyzing the CO2 hydration to bicarbonate and H
þ, and it bound the clinically used sulfonamide
inhibitor acetazolamide with high affinity (KI of 10 nM). Unlike the wild-type enzyme, which is not inhibited by chloride, bromide, or
iodide (KIs of 73–215 mM), the mutant is inhibited in the submicromolar range by these anions (KIs of 0.37–0.73 mM).Elevated sweat chloride concentrations, as detectable in
the sweat test, serve as the classical diagnostic criterion
for cystic fibrosis (CF [MIM 219700]).1 Although all CF
patients have a positive sweat test (sweat chloride
concentrations above 60 mmol/L), not all individuals
with a positive sweat test have CF. Abnormal sweat chlo-
ride levels have been demonstrated in malnutrition, meta-
bolic disorders (mucopolysacharidoses, type I fucosidosis,
and glycogen storage diseases), dermatological diseases
(congenital ectodermal dysplasia and atopic dermatitis),
and various endocrine disorders, such as panhypopituitar-
ism, Addison disease, isolated adrenocorticoid deficiency,
vasopressin-resistant diabetes insipidus, hypothyroidism,
and hypoparathyroidism.2 Hyperchlorhidrosis (MIM
143860), autosomal-recessive heredity of isolated exces-
sive chloride exceretion, is an entity whose existence is
in dispute. Greenburg et al.3 described 7- and 15-year-old
Puerto Rican brothers with elevated sweat chloride. The
younger brother was initially studied because of hypona-
tremic dehydration following sweating. Further analysis
of the family identified an abnormal sweat test in the other
brother. Both were generally healthy, with no evidence of
CF or other disorders causing elevation of sweat chloride.
Four other siblings were unaffected. The parents were not
related. An unpublished report of the same family by
Punnett (OMIM 143860) indicated that the two brothers
were sterile (however, one had a 47,XXY karyotype) and
suggested that they did have mild CF. Regretfully, the
family was not available for molecular genetic testing for
resolution of the conflicting claims.
We have identified a large Israeli Bedouin kindred pre-
senting with an apparently autosomal-recessive pheno-
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The Americanindividuals (IV:1 and IV:3; Figure 1) had undergone a sweat
test as part of routine screening for CF when they pre-
sented with hyponatremic dehydration with coincidental
gastroenteritis at infancy. The quantitative pilocarpine
iontophoresis test (QPIT) was performed for the collection
of sweat and a chemical analysis of its chloride content, per
the standard guidelines of the Cystic Fibrosis Foundation.1
In some detail, at least 50–100 mg of sweat was collected.
When a macroduct coil was used for collection, sweat
was stimulated with a disposable Pilogel electrode using
the Webster Sweat Inducer for 5 min. After 30 min, 15 ml
was considered to be the minimum acceptable sample.
Sweat chloride values of more than 60 mmol/L of chloride
were considered to be abnormal. Screening of the entire
kindred (Figure 1) identified seven individuals with sweat
chloride levels substantially above 60 mmol/L (Table 1).
The medical records of all seven affected individuals were
reviewed, and all family members underwent careful clin-
ical evaluation by a pediatric pulmonologist, a pediatric
gastroenterologist, and a clinical geneticist. The study
was approved by the institutional review board of Soroka
Medical Center, and informed consent was obtained
from all participants or their legal guardians. All seven
affected individuals (and not their healthy siblings)
reported dramatically excessive amounts of visible salt
precipitates in sweat (especially in the nape). Five of the
seven individuals (yet none of their nonaffected siblings)
were hospitalized once before the age of one year for hypo-
natremic dehydration, with reports of poor feeding and
slow weight gain. Sodium supplementation was effective
in the treatment of hyponatremia in all cases. By one
year of age, all affected individuals achieved normal height
and weight and had no further feeding problems.logy in the Negev (NIBN), Ben Gurion University, Beer-Sheva, 84105 Israel;
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Figure 1. Pedigree of the Affected Israeli-Bedouin Kindred
The pedigree is compatible with autosomal-recessive heredity.Psychomotor development and intelligence of affected
individuals was normal, and physical examination of all
affected individuals demonstrated no further abnormal
findings or dysmorphism. All affected individuals were
too young to allow investigation of fertility. As mentioned
above, medical records of five of the seven affected individ-
uals demonstrated that they had a single episode of hypo-
natremic dehydration during infancy (mostly following
mild gastroenteritis), with steatorrhea recorded in two of
the cases. However, aside from these single episodes, repeat
tests of serum and urinary electrolytes (including sodium
and potassium) were normal in all affected individuals, as
were serum amylase and fecal elastase. Renal function
tests, renin-aldosterone axis function tests, urinalysis,
and blood and urinary pH tests were normal. None of
the affected individuals had any abnormal respiratory
symptoms or signs, and none had chronic rhinitis or
nasal polyps. All affected family members had normal
pulmonary function tests (FEV1). Nasal potential differ-
ence (NPD) measurement, an electrophysiological test
that assesses CF transmembrane conductance regulator
(CFTR) activity and is a recognized diagnostic tool in CF,
was tested in six affected individuals as previously
described4 and was normal (data not shown).
Assuming autosomal-recessive heredity due to a founder
effect, homozygosity mapping was performed to elucidate
the molecular basis of the clinical phenotype. DNA
samples of the seven affected individuals and 19 nonaf-
fected family members were obtained with informed
consent after approval of the Soroka Medical Center insti-
tutional review board. DNA was isolated from whole
blood of affected individuals with the use of the FlexiGene
DNA Extraction Kit per the manufacturer’s instructions
(QIAGEN) as previously described.5 Lymphoblast cell lines
were established by Epstein-Barr virus (EBV) transforma-
tion via standard methods.6 We first tested the affected
individuals for homozygosity at the locus of CFTR by using714 The American Journal of Human Genetics 87, 713–720, Novembmicrosatellite markers as previously described (data not
shown).7 In brief, microsatellite markers were derived
fromMarshfield maps. Intronic primer pairs were designed
with the Primer 3 (version 0.4.0) software, based on DNA
sequences obtained from the UCSC Genome Browser
(sequences available on request). PCR products were sepa-
rated on polyacrylamide gel with the use of silver staining
for detection.7 Affected individuals did not share homozy-
gosity at the CFTR locus (data not shown).
Next, we performed genome-wide linkage analysis
testing seven affected individuals (Figure 1; individuals
IV:1, IV:3, IV:5, IV:6, IV:7, IV:15, and IV:17), four obligate
carrier parents (Figure 1; individuals III:1, III:2, III:3, and
III:4), and one healthy sibling (Figure 1; individual IV:16).
A genome-wide scan was performed at the microarray
facility at the Biological Services Department of BenGurion
University, with the use of the high-density-genotyping
GeneChip Human Mapping 250K Array Nsp (Affymetrix)
according to manufacturer’s guidelines as previously
described.8 Homozygosity-by-descent analysis was carried
out with the use of an in-house-generated tool for homozy-
gosity mapping (B.M., unpublished data). The analysis
identified a segment of homozygosity on chromosome 15
that was common to all seven patients. Few additional
significantly smaller regions of shared homozygosity,
shorter than 1 Mb, were spotted. However, because none
of thesewere containedwithin larger stretches of individual
homozygosity, we focused on the chromosome 15 locus.
The interval of homozygosity was confirmed, and fine
mapping was performed by testing DNA samples of all
seven affected individuals and 19 nonaffected members of
the extended family, then genotyping with additional
microsatellite markers derived from Marshfield maps or
with ones designed with the Tandem Repeats Finder (TRF)
program and the UCSCGenome Browser. Analysis was per-
formedwith the use ofmarkers within the interval between
D15S155 and D15S984: chr15:61090417-61090468,er 12, 2010
Table 1. Sweat Test Measurements of Individuals in the Israeli
Bedouin Kindred Studied
Individual No. Sweat Test (mmol/L)
III:1 41
III:2 34
IV:1 110
IV:2 ND
IV:3 156
IV:4 25
III:3 56
III:4 54
IV:5 95
IV:6 128
IV:7 116
IV:8 35
IV:9 ND
IV:10 34
IV:11 58
IV:12 56
IV:13 59
IV:14 52
III:5 29
IV:15 155
IV:16 ND
IV:17 85
IV:18 21
IV:19 9.5
IV:20 19
IV:21 30
ND, not done.D15S970, D15S1036, D15S987, D15S1507, D15S153,
D15S988, D15S983, D15S650, D15S131, D15S124, and
D15S818. Haplotypes for the 26 family members were
manually constructed and analyzed with GENEHUNTER.
All of the obligatory carriers were shown to be heterozy-
gous for the haplotype. Furthermore, most unaffected
family members were heterozygous for this haplotype.
As seen in Figure 2, an 18.4 cM interval of homozygosity
betweenmarkers chr15:61090417-61090468 and D15S650
(according to the Marshfield map), corresponding to
~9.17 Mb, was common to all affected individuals in the
family studied. To determine the exact borders of the
homozygosity region shared by all of the affected individ-
uals, we integrated the data from the polymorphic
markers studies with the data of the SNP arrays. The
phenotype-associated homozygosity locus was shown to
lie within 11 cM (corresponding to ~5.6 Mb) betweenThe Americanchr15:61090417-61090468 and rs16949924 at physical
positions 61090421 and 66727347 (UCSC Genome
Browser, February 2009 assembly), respectively.
Two-point LOD-score calculation was performed with
the use of SUPERLINK,9 assuming an autosomal-recessive
mode of inheritance with a penetrance of 0.99, a disease
mutant gene frequency of 0.0001, and a uniform distribu-
tion of allele frequencies. For LOD-score calculations, the
number of alleles was set as the number observed in the
pedigree, rather than as the number observed elsewhere,
to provide a conservative estimate of the LOD score.
Through testing of the entire 26 samples of the kindred,
the maximum two point LOD score calculated was
[Zmax] ¼ 6.65 (q ¼ 0.0) at D15S153.
We then proceeded to sequence candidate genes within
the identified locus. To obtain a prioritized list of the 56
candidate genes within the locus, we used our Syndrome
to Gene (S2G) software,10 using CFTR as a reference gene.
The software selects for any syndrome a prioritized list of
candidate genes, on the basis of their known molecular
interactions with genes associated with phenotypically
similar syndromes. Candidate genes were sequenced
from lymphoblastoid cDNA of patients: RNAwas extracted
from cultured cells of EBV-transformed lymphoblastoid
cell lines with the use of the RNeasy Mini Kit (QIAGEN),
and cDNA was reverse transcribed by the Verso RT-PCR
Kits (TAMAR) as previously described.6 Primer pairs for
PCR amplification from cDNA and/or exons of genomic
DNA (including flanking intron sequences) of the genes
in the putative chromosome 15 locus were designed on
the basis of the known mRNA and genomic sequences
with the use of Primer 3. Primer sequences and PCR
conditions are available upon request. PCR products
were directly sequenced with the ABI PRISM 3730 DNA
Analyzer according to the manufacturer’s protocols
(Applied Biosystems, Foster City, CA, USA). Sequence
variations were confirmed by bidirectional sequencing.
Of the top candidate genes suggested by S2G, we
sequenced SLC24A1 (MIM 603617) (encoding solute
carrier family 24, a potassium-dependent sodium/calcium
exchanger)11 and CA12 (MIM 603263). Testing cDNA
and genomic DNA from lymphoblastoid cells of an
affected individual, the entire coding regions and flanking
~50 bp intron sequences of the two genes were sequenced.
No mutation was found in SLC24A. A missense mutation
(c.427G>A) was identified in exon 4 of CA12 (GenBank
accession number NM_001218.3), predicted to generate
p.Glu143Lys mutant carbonic anhydrase 12 protein
(Figure 3). Testing for the CA12 mutation in the entire
family and controls was performed via restriction analysis,
based on the fact that the mutation creates an MnlI
restriction site that does not exist in the wild-type
sequence. PCR amplification of genomic DNA was per-
formed with the use of the following primers: F-50-TCCA
GTCTCGCTACAGTGC-30 and R-30-AGAGCAGCCACTGC
CAGACT-50.MnlI restriction analysis of the PCR amplicons
generated differential cleavage products of the wild-typeJournal of Human Genetics 87, 713–720, November 12, 2010 715
Figure 2. Fine Mapping of the Chromosome 15 Locus
Partial pedigree of the large Israeli-Bedouin kindered and disease-haplotype segregation. The two lines indicate a crossing over event.
Disease associated haplotype shown in boxes. Markers chr15:61090417-61090468 and rs16949924 define the minimal homozygosity
locus associated with the disease (Individual IV:15). The affected haplotype is shaded. Numbers below symbols correspond to the posi-
tion of individuals within the pedigree (see Figure 1). Blank spaces indicate non-genotyped markers.(uncut, 139 bp) versusmutant (95 bp and 44 bp fragments)
allele. Fragments were separated by electrophoresis on 3%
agarose gel. Restriction analysis showed complete segrega-
tion (and thus full penetrance) of the mutation with the
disease-associated phenotype in all investigated family
members, heterozygosity in all obligatory carrier parents,
and no homozygosity in nonaffected individuals. Of 300
healthy Bedouin controls, the mutation was found in716 The American Journal of Human Genetics 87, 713–720, Novembonly one individual in a heterozygous state and in none
in a homozygous state.
To test whether the CA12 missense mutation alters the
enzymatic activity of the encoded carbonic anhydrase
(CA [EC 4.2.1.1]), the mutant p.Glu143Lys CA XII was
cloned to generate GST-tagged mutant protein as previ-
ously reported by this group for the wild-type enzyme.12,13
The enzyme was purified in two steps as described earlierer 12, 2010
Figure 3. The c.427G>A (p.Glu143Lys) Mutation in Exon 4 of CA12, and CA12 Expression
Sequence analysis is shown for an unaffected individual (A), an obligatory carrier (B), and an affected individual (C). (D) ConSeq analysis
for the p.Glu143Lys residue (marked with an arrow), demonstrating conservation grade 9 (highly conserved). (E) RT-PCR demonstrating
that CA12 (as well as actin control) are transcribed in normal human foreskin (1,2) and arm skin (3,4). PCR primer sequences available
upon request. Lane 5 ¼ size marker. Lanes 6,7 represent negative controls for CA12 and actin PCR reactions, with no cDNA template.for the wild-type CA XII,12,13 and its activity was assayed
by a stopped-flowmethod for the physiological reaction.14
An Applied Photophysics stopped-flow instrument was
used for assaying the CA-catalyzed CO2 hydration
activity.14 Phenol red (at a concentration of 0.2 mM) was
used as an indicator, working at the absorbance maximum
of 557 nm, with 20 mMHEPES (pH 7.4) and 20 mMNaBF4
(for maintaining constant ionic strength), following the
initial rates of the CA-catalyzed CO2 hydration reaction
for a period of 10–100 s. The CO2 concentrations ranged
from 1.7 to 17 mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor,
at least six traces of the initial 5%–10% of the reaction
were used for determining the initial velocity. The uncata-
lyzed rates were determined in the same manner and sub-
tracted from the total observed rates. Stock solutions of
inhibitor (10 mM) were prepared in distilled-deionized
water, and dilutions up to 0.01 mM were performed there-
after with distilled-deionized water. Inhibitor and enzyme
solutions were preincubated together for 15 min at room
temperature prior to the assay, in order to allow for the
formation of the E-I complex. The inhibition constants
were obtained by nonlinear least-squares methods with
the use of PRISM 3, whereas the kinetic parameters for
the uninhibited enzymes were from Lineweaver-Burk
plots, as reported earlier,12,13 and represent the mean
from at least three different determinations. The catalytic
activity of p.Glu143Lys CA XII compared to that of wild-
type CA XII and other members of the a-CA family, such
as CA I, II, IV, VI, and IX, are shown in Table 2. Inhibition
data with acetazolamide, a clinically used sulfonamide
inhibitor [4] are also shown in Table 2. Table 3 and Figure 4The Americanpresent the inhibition data of the mutant and wild-type
CA XII with anions, compared to those of the physiologi-
cally relevant enzymes CA I and II.13,15
Themutant CA XII investigated in this study has a gluta-
mic acid mutated to a lysine at position 143. This amino
acid residue is found near the third Zn(II) ligand
(His145), being in a highly conserved protein region in
all mammalian CA isozymes.15 Indeed, the residues in
the neighborhood of the three histidine residues acting
as Zn(II) ligands are conserved in all CAs, which is probably
due to the fact that the tetrahedral geometry of Zn(II) is
essential for the proper catalytic activity of the enzyme.
In fact, in addition to the three His ligands mentioned
above, the metal ion is also coordinated by a water mole-
cule and a hydroxide ion that acts as nucleophile in the
reactions catalyzed by these enzymes. This nonprotein
zinc ligand is also involved in extensive hydrogen bonding
with amino acid residues in its neighborhood (primarily
conserved Thr and Glu residues), which assures both its
proper orientation and its nucleophility needed to act on
the substrates of the enzyme. Normally, perturbations of
such hydrogen bonds will lead to a drastic diminution of
the catalytic activity.15,16 However, unexpectedly, the
mutant investigated here, in which a negatively charged
amino acid residue (Glu143) near the third Zn(II) ligand
is replaced by a positively charged one (Lys), still maintains
a high enough catalytic activity for the physiologic reac-
tion. Indeed, the mutant enzyme showed around 70%
activity, as compared to the wild-type enzyme, for the
physiologic CO2 hydration reaction, with a kcat of 3.0 3
105 s1 and a kcat/KM of 2.5 3 10
7 M1s1 (Table 2).
Furthermore, this mutant enzyme was highly inhibitedJournal of Human Genetics 87, 713–720, November 12, 2010 717
Table 2. Kinetic Parameters and Inhibitory Properties of Acetazolamide for Different CA Isozymes, Including the Mutant CA XII15
Isoenzyme kcat (s
1) KM (mM) kcat/KM (M
1s1) KI (Acetazolamide
a) (nM) Subcellular Localization
hCA I 2.0 3 105 4.0 5.0 3 107 250 cytosol
hCA II 1.4 3 106 9.3 1.5 3 108 12 cytosol
hCA IV 1.1 3 106 21.5 5.1 3 107 74 GPI-anchored
hCA VI 3.4 3 105 6.9 4.9 3 107 11 secreted
hCA IX (catalytic domain) 3.8 3 105 6.9 5.5 3 107 25 transmembrane
hCA IX (full length) 1.1 3 106 7.5 1.5 3 108 16 transmembrane
hCA XII 4.2 3 105 12.0 3.5 3 107 5.7 transmembrane
hCA XII mutant 3.0 3 105 11.9 2.5 3 107 9.9 transmembrane
a 5-acetamido-1,3,4-thiadiazole-2-sulfonamide.
Table 3. Inhibition Constants for Anionic Inhibitors of Human
Isozymes hCA I, hCAII, and hCAXII and Mutant hCA XII for the CO2
Hydration Reaction at 20C14
Inhibitor
KI
a [mM]
hCA I hCA II hCA XII Mutant hCA XII
F > 300 > 300 0.56 0.59
Cl 6 200 73 0.49
Br 4 63 82 0.37
I 0.3 26 215 0.73
CNO 0.0007 0.03 0.73 0.58
SCN 0.2 1.6 0.80 0.52
CN 0.0005 0.02 0.001 0.004
N3
 0.0012 1.5 0.08 0.005
HCO3
 12 85 0.75 0.67
CO3
2 15 73 0.64 0.47
NO3
 7 35 79 0.58
NO2
 8.4 63 94 0.64
HS 0.0006 0.04 4.85 0.54
HSO3
 18 89 0.84 0.92
SO4
2 63 > 200 0.77 0.74
BF4
 > 200 > 200 > 200 > 200
H2NSO3H
b> 0.021 0.39 0.70 7.6 mM
H2NSO2NH2 0.31 1.13 0.83 6.5 mM
PhB(OH)2 58.6 23.1 0.80 6.1 mM
PhAsO3H2
b 31.7 49.2 0.84 5.2 mM
a Errors were in the range of 3%–5% of the reported values, from three
different assays.
b As sodium salt.by acetazolamide, a clinically used sulfonamide,15,16 with
an inhibition constant of 10 nM (Table 2), in the same
order of magnitude as the wild-type CA XII (which is
anyhow better inhibited by acetzolamide, with a KI of
5.7 nM).
We have also investigated the inhibition of the mutant
CA XII with a series of anions, some of which are physio-
logically relevant species,15 such as chloride, sulfate, bicar-
bonate, etc. (Table 3). Data in Table 3 and Figure 4 show
that the mutant CA XII investigated here is much more
sensitive to inhibition by anions, unlike the wild-type
CA XII, which was generally weakly inhibited by halides,
except fluoride.13 Thus, the mutant CA XII had an inhibi-
tion constant for halides of 0.49mM for chloride, 0.37mM
for bromide, and 0.73 mM for iodide, being thus 148.9
times more sensitive to chloride inhibition than the
wild-type enzyme, 221.6 times more sensitive to bromide,
and 294.5 times more sensitive to iodide, as compared to
the wild-type CA XII. Bicarbonate, carbonate, and pseudo-
halides generally showed similar inhibitory activity against
the two enzymes (in the millimolar range), although the
mutant was usually slightly better inhibited as compared
to the wild-type CA XII. The only anion that was not
at all inhibitory against both proteins was tetraflurobo-
rate. Cyanide and azide were quite potent micromolar
inhibitors of the mutant CA XII (inhibition constants of
4–5 mM). Sulfamic acid, sulfamide, phenylboronic acid,
and phenylarsonic acid were also low micromolar inhibi-
tors of the mutant CA XII (inhibition constants in the
range of 5.2–7.6 mM), whereas they were submillimolar
ones against wild-type CA XII. Thus, the p.Glu143Lys CA
XII shows an inhibition profile with this class of inhibitors
very different from that of the wild-type enzyme and the
cytosolic, ubiquitous CA I and II (Table 3). It is highly
unusual that a point mutation in a CA isoform leads to
such a drastic change in the affinity for anion inhibi-
tors.15,16 It is tempting to speculate that the positively
charged amino acid residue (Lys143) near the third Zn(II)
ligand present in this mutant is the main reason for this
enhanced affinity for anion inhibitors, but it is probable
that the hydrogen bonding network in the neighborhood718 The American Journal of Human Genetics 87, 713–720, Novembof the catalytic center is completely changed as a result of
this mutation.
The CA metalloenzymes catalyze a very simple but
essential physiological reaction, carbon dioxide hydration
to bicarbonate and protons.15 This reaction also occurser 12, 2010
Figure 4. Inhibition Constants for Anionic Inhibitors of Human
Wild-Type and Mutant hCA XII, for the CO2 Hydration Reaction,
at 20C14without a catalyst, but it is too slow. Given that CO2, bicar-
bonate, and protons are essential molecules and ions in
many important physiologic processes in all life kingdoms
(Bacteria, Archaea, and Eukarya), throughout the phyloge-
netic tree, and relatively high amounts of them are present
in different tissues or cell compartments of all such organ-
isms, it is no wonder that CAs evolved independently at
least five times, with five genetically distinct enzyme fami-
lies known to date: the a-, b-, g-, d- and z-CAs.15
Inmany organisms these enzymes are involved in crucial
physiological processes connected with respiration and
transport of CO2 and bicarbonate, pH and CO2 homeo-
stasis, electrolyte secretion in a variety of tissues andorgans,
biosynthetic reactions (such as gluconeogenesis, lipogen-
esis, and ureagenesis), bone resorption, calcification,
tumorigenicity, and many other physiologic or pathologic
processes (thoroughly studied in vertebrates),15,16 whereas
in algae, plants, and some bacteria they play an important
role in photosynthesis and other biosynthetic reactions.15
In diatoms d- and z-CAs play a crucial role in CO2
fixation.15,16
So far, 16 different a-CA isoforms have been isolated and
characterized in mammals, where they play important
physiological roles, as briefly outlined above. Some of
them are cytosolic (CA I, CA II, CA III, CA VII, and CA
XIII), others are membrane-bound (CA IV, CA IX, CA XII,
CA XIV, and CA XV), CAVA and CAVB are mitochondrial,
and CA VI is secreted in saliva and milk. Three acatalytic
forms are also known: the CA-related proteins (CARP),
CARP VIII, CARP X, and CARP XI, which seem to be cyto-
solic proteins as well.15 The mammalian CAs were the
first such enzymes isolated and studied in detail,15 and
many of them are established therapeutic targets with
the potential to be inhibited or activated to treat a wide
range of disorders.16
Isozymes CA IX and CA XII are predominantly found in
tumor cells and show a restricted expression in normal
tissues.15 It has been recently proven that by efficiently
hydrating carbondioxide toprotons andbicarbonate, these
CAs contribute significantly to the extracellular acidifica-The Americantion of solid tumors, whereas their inhibition reverts this
phenomenon to a certain extent.15 CA IX and CA XII are
overexpressed in many such tumors in response to the
hypoxia inducible factor (HIF) pathway, and research on
the involvement of these isozymes in cancer has progressed
significantly in recent years. Interestingly, an alternatively
spliced isoform of CA XII was demonstrated in diffusely
infiltrating astrocytic gliomas.17 There are recent efforts to
design inhibitors against these antitumor targets.16 In rele-
vance to the present report, it is of interest to note thatCA II
has been shown to be expressed in sweat glands18 and that
its inhibitor, topiramate, has been demonstrated to induce
oligohydrosis in humans and in mice.18,19
CA XII transcripts were previously demonstrated in
normal human kidney, colon, prostate, pancreas, ovary,
testis, lung, eye, and brain.20–22 CA XII is also overex-
pressed in the eyes of glaucoamtouos patients, and its inhi-
bition may lead to a strong antiglaucoma effect.15,22 Using
RT-PCR, we have now demonstrated that CA XII is also
transcribed in human skin (Figure 3E). This finding is in
line with previous studies, showing that different proteins
that participate in the regulation of electrolyte transport
as well as in acid base balance in the kidney and the
colon are expressed in the sweat glands. For example, in
isolated sweat glands, bumetanide (an inhibitor of the
sodium-potassium and chloride cotransportes NKCC1
and NKCC2) inhibits sweat secretion. Immunoelectron
microscopy demonstrated abundant NKCC1 and NHE1
labeling of the basolateral plasma membrane of mouse
sweat glands.14 The presence of an Naþ/Hþ exchanger of
isoform 1 (NHE1) in the human eccrine sweat duct has
also been shown with the use of an NHE1 antibody.15 In
addition, normal human epidermis stained positively for
CFTR, a cAMP-dependent chloride channel protein, as
densely as did the eccrine sweat gland.16
We have thus shown that a consistent autosomal-
recessive phenotype of hyperchlorhidrosis does exist and
should be considered in the differential diagnosis of a posi-
tive sweat test, especially in the context of hyponatremic
dehydration during infancy. We have further demon-
strated that the phenotype can be caused by a homozygous
missense mutation in CA12. The mutant protein demon-
strated 70% CA activity as compared to the wild-type
enzyme. This might explain why the phenotype is mild,
with no significant gastrointestinal or renal involve-
ment—despite the fact that CA12 is expressed in those
tissues. It is also feasible that in the kidney and colon
(yet not in the skin) CA12 activity is complemented by
that of other enzymes, making the 30% reduction in
activity insignificant in those tissues. Unlike the wild-
type enzyme, which is not inhibited by chloride, bromide,
or iodide (KIs of 73–215 mM), the mutant is inhibited
in the submicromolar range by these anions (KIs of
0.37–0.73 mM). Thus, we demonstrate that the CA12
mutation reduces the CA activity and causes a dramatic
change in chloride-mediated feedback regulation of this
enzyme, leading to excessive chloride secretion in sweat.Journal of Human Genetics 87, 713–720, November 12, 2010 719
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